Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis

He, Anna; Spelman, Tim; Jokubaitis, Vilija; Havrdova, Eva; Horakova, Dana; Trojano, Maria; Lugaresi, Alessandra; Izquierdo, Guillermo; Grammond, Pierre; Duquette, Pierre; Girard, Marc; Pucci, Eugenio; Iuliano, Gerardo; Alroughani, Raed; Oreja-Guevara, Celia; Fernandez-Bolanos, Ricardo; Grand'Maison, Francois; Sola, Patrizia; Spitaleri, Daniele; Granella, Franco; Terzi, Murat; Lechner-Scott, Jeannette; Van Pesch, Vincent; Hupperts, Raymond; Luis Sanchez-Menoyo, Jose; Hodgkinson, Suzanne; Rozsa, Csilla; Verheul, Freek; Butzkueven, Helmut; Kalincik, Tomas

doi:10.1001/jamaneurol.2014.4147

Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis

He A., Spelman T., Jokubaitis V., Havrdova E., Horakova D., Trojano M., ...Daha Fazla

JAMA NEUROLOGY, cilt.72, sa.4, ss.405-413, 2015 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 72 Sayı: 4
Basım Tarihi: 2015
Doi Numarası: 10.1001/jamaneurol.2014.4147
Dergi Adı: JAMA NEUROLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.405-413
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

IMPORTANCE After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicians advocate therapy switch, but the relative effectiveness of different switch decisions is often uncertain.